Skip to content

Study · Non-randomized trial · n = 21 · 1983

5 results

Desmopressin response of enuretic children. Effects of age and frequency of enuresis.

Post EM, Richman RA, Blackett PR, Duncan KP, Miller K

American journal of diseases of children (1960)1 Oct 1983Cited by 49 (Europe PMC)

PMID6351590 (opens in a new tab)DOI10.1001/archpedi.1983.02140360026009 (opens in a new tab)PepBankPUB-06351590
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    After desmopressin treatment, only four of 21 responders reported a persistent effect.

    In plain wordsAfter desmopressin treatment, only four of 21 responders reported a lasting effect.

    Peptide
    Desmopressin
    Outcome
    Not applicablePersistent posttreatment response
    Study

    n = 21

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Responders with persistent effect
    4 children
    posttreatment period, of 21 drug responders

    Source sentences

    Summary
    During the posttreatment period, only four of the 21 drug responders reported a persistent effect.
    1 context sentence
    Summary · context
    To characterize the children with enuresis likely to respond to desmopressin acetate, we performed a double-blind crossover study that included the use of a placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    Among 17 children aged 9 years or older with four to seven dry nights during the two-week baseline, 12 (71%) had eight to 14 dry nights with desmopressin.

    In plain wordsAmong children aged 9 years or older with four to seven baseline dry nights, 12 (71%) responded to desmopressin.

    Peptide
    Desmopressin
    Outcome
    Not applicableResponse in older children with baseline dry nights
    Study

    n = 17

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · two weeksAs given in this study (human).

    Measurements

    Responders
    12 children
    older subgroup
    Response proportion
    71%
    older subgroup

    Source sentences

    Summary
    Among the 17 children aged 9 years or older, with four to seven dry nights during the two-week baseline period, 12 children (71%) responded to desmopressin (eight to 14 dry nights).
    1 context sentence
    Summary · context
    To characterize the children with enuresis likely to respond to desmopressin acetate, we performed a double-blind crossover study that included the use of a placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    None of the 15 children younger than 9 with fewer than three baseline dry nights responded to desmopressin.

    In plain wordsNone of 15 younger children with few baseline dry nights responded to desmopressin.

    Peptide
    Desmopressin
    Outcome
    Not applicableResponse in younger children with few baseline dry nights
    Study

    n = 15

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · two weeksAs given in this study (human).

    Source sentences

    Summary
    In contrast, none of the 15 children younger than 9 years of age with fewer than three dry nights before therapy responded.
    2 context sentences
    Summary · context
    Among the 17 children aged 9 years or older, with four to seven dry nights during the two-week baseline period, 12 children (71%) responded to desmopressin (eight to 14 dry nights).
    Summary · context
    To characterize the children with enuresis likely to respond to desmopressin acetate, we performed a double-blind crossover study that included the use of a placebo.
  4. 04HumanNon-randomized trialEfficacy outcome

    During desmopressin treatment, six children (12%) had 13 or 14 dry nights.

    In plain wordsDuring desmopressin treatment, six children (12%) had 13 or 14 dry nights.

    Peptide
    Desmopressin
    Outcome
    Not applicable13 or 14 dry nights
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · two weeksAs given in this study (human).

    Measurements

    Children
    6 children
    13 or 14 dry nights
    Proportion
    12%
    13 or 14 dry nights

    Source sentences

    Summary
    During the two weeks of desmopressin administration, six children (12%) had 13 or 14 dry nights, and 15 children (29%) had eight to 12 dry nights.
    1 context sentence
    Summary · context
    To characterize the children with enuresis likely to respond to desmopressin acetate, we performed a double-blind crossover study that included the use of a placebo.
  5. 05HumanNon-randomized trialEfficacy outcome

    During desmopressin treatment, 15 children (29%) had eight to 12 dry nights.

    In plain wordsDuring desmopressin treatment, 15 children (29%) had eight to 12 dry nights.

    Peptide
    Desmopressin
    Outcome
    Not applicableEight to 12 dry nights
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · two weeksAs given in this study (human).

    Measurements

    Children
    15 children
    eight to 12 dry nights
    Proportion
    29%
    eight to 12 dry nights

    Source sentences

    Summary
    During the two weeks of desmopressin administration, six children (12%) had 13 or 14 dry nights, and 15 children (29%) had eight to 12 dry nights.
    1 context sentence
    Summary · context
    To characterize the children with enuresis likely to respond to desmopressin acetate, we performed a double-blind crossover study that included the use of a placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.